Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 5 of 11

Bio‑Works Technologies reported that 1,199,471 TO 2 warrants were exercised in the fifth exercise period (2–16 Jan 2026), raising SEK 1,199,471 before issue-related costs. The exercise increases the share count by 1,199,471 to 99,424,593 shares and raises share capital by SEK 119,947.1, producing approximately 1.2% dilution for non‑exercising shareholders; conversion to ordinary shares is expected around 29 Jan 2026. There remain 17,514,777 TO 2 outstanding and the next exercise window is 1–16 April 2026.

Analysis

Market structure: The direct winners are warrant holders who exercise when the market price > SEK1 (they convert leverage to equity) and Bio‑Works which collects incremental cash (SEK1.20m this round; SEK17.5m if remaining TO 2 are fully exercised). Current dilution from this exercise is ~1.2%; if the remaining 17,514,777 TO 2 are all exercised by Q3 2027 the share count would rise to ~116.94m (≈+17.6% dilution from today), implying recurring downward pressure on per‑share metrics each quarter with exercise windows.

Risk assessment: Immediate (days) impact is small — token cash and marginal dilution; short‑term (weeks/months) risk centers on the next exercise window (1–16 Apr 2026) creating concentrated sell/supply; long‑term (to Q3 2027) the main tail risk is cumulative dilution and potential FDI screening if a single investor crosses a 10%+ vote threshold, which could trigger regulatory delays or forced disclosures. Hidden dependency: serial warrant exercises function as recurring financing — signals potential cash strain and makes equity returns path‑dependent on exercise cadence rather than operating progress.

Trade implications: Direct play is stock exposure to capture operational upside if fundamentals improve, but size for retailable illiquidity: 1–3% portfolio position in BIOWKS (Spotlight: BIOWKS) with tight stops; where listed TO 2 warrants trade, consider shorting them versus owning underlying equity when warrants trade >20% premium to intrinsic (share price−SEK1), particularly ahead of the Apr 1–16 window. Use covered‑call overlays to monetize optionable illiquidity and reduce dilution risk; avoid long‑dated call buys unless volatility is cheap and liquidity exists.

Contrarian angle: The market likely underestimates the behavioral selling pattern tied to each exercise window — recurring small infusions can create predictable, temporary sell pressure and buying opportunities; historical parallels: small‑cap biotech issuers that rely on serial warrant financing typically underperform until clear operating cash‑flow or a large strategic investor appears. Unintended consequence: aggressive warrant conversion by insiders or distributors could consolidate float and trigger FDI notification thresholds, causing sudden liquidity and regulatory noise.

Key Decisions for Investors

• Establish a tactical 1–3% long position in BIOWKS (Spotlight ticker: BIOWKS) within 10 trading days if shares trade at or below SEK1.50; set a 20% stop‑loss and target 30–50% upside over 6–12 months, trimming into strength and especially ahead of each exercise window (next: 1–16 Apr 2026).
• If TO 2 warrants quote at >20% premium to intrinsic value (market price > (share price − SEK1) ×1.20), initiate a small short‑warrant trade sized to no more than 0.5–1.0% of NAV and cover during the close of the Apr 2026 exercise window, capturing over‑leveraged premium that collapses on conversion/sell flow.
• Run a pair trade: long BIOWKS 2% vs short OMXSPI (Sweden all‑share index) 1% nominal for 3–6 months to isolate company‑specific upside; rebalance monthly and close/scale if cumulative exercised TO 2 causes >10% float increase or if BIOWKS outperforms the index by >25%.
• Monitor within 30–90 days: (a) filings for any investor crossing 10%+ (FDI Act trigger) — if seen, pause new longs until clearance; (b) warrant outstanding reductions and monthly volume — exit long positions if remaining TO 2 exercises imply >10% incremental dilution or if realized selling spikes around the Apr 2026 window.